Ascentage Pharma's lisaftoclax, combined with acalabrutinib, received Breakthrough Therapy Designation from China's NMPA for treating treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). This designation accelerates development and review, reflecting the urgent need for improved therapies in CLL/SLL, a cancer affecting mainly older adults with rising incidence in China. Lisaftoclax is already approved in China for previously treated CLL/SLL patients and is undergoing global Phase III trials for first-line use. This advancement may lead to faster patient access to this novel treatment option.
Ascentage Pharma’s lisaftoclax breakthrough therapy designation provides context for health sector activity. For readers following Health stocks, here is Pluang's market snapshot as of Oct 21, 2026 05:01 WIB: Out of 150 priced US Health stocks, 129 rose and 21 fell today. Among notable movers, AMWL rose 7.46% to USD 13.25 with a typical hold time of 62 days, contrasting with DYN and ERAS, which gained 7.29% and 7.27% respectively but have much shorter typical hold times of 2 days and 100% buy order activity on DYN and ERAS.
Medical Informatics Corp. has launched the Sickbay Experience Demo Center at Texas Medical Center's Helix Park, showcasing its FDA-cleared Sickbay platform. This interactive center demonstrates how real-time patient data from various medical devices ...
Grupo Aeroportuario del Pacífico reported Q3 2026 earnings per share of $2.66 and revenue of $632.9 million, both below analyst expectations. Despite the miss, the company saw a 13.2% rise in revenue excluding construction services and a 19.2% increa...
Northern Trust is set to report its Q3 2026 earnings with analysts forecasting a 24.9% rise in earnings per share to $2.86 and an 11.8% increase in revenue to $2.26 billion. Growth is driven by an 11.4% increase in net interest income and a 12.1% ris...
Moody's is expected to report Q3 2026 earnings of around $4.25 per share on revenue near $2.08 billion, driven by steady demand for credit ratings and growth in Moody's Analytics, especially from recurring subscriptions and AI tools. While Moody's In...
Investing $100,000 in four popular covered call ETFs reveals a $4,632 annual income difference, with NEOS IWMI paying the most but ranking lower in total returns. IWMI offers a 15.1% yield by selling out-of-the-money calls on the Russell 2000, balanc...
